関連する実験動画
Updated: Jan 7, 2026

04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
1.2K
うつ病および双極性障害における混合性特徴:最新の系統的レビュー
Veronica Grasso1, Carolina Hernandorena2, Micaela Dines3
1Centro Integrador de psicoterapias Conductuales Contextuales (Fundación CIPCO), Córdoba, Argentina.
Journal of affective disorders
|December 25, 2025
まとめ
混合性特徴は、大うつ病性障害(MDD)および双極性障害(BD)で一般的であり、BDではほぼ2倍多く発生します。有病率は、使用される診断基準によって大きく異なります。
科学分野:
- 精神医学および行動科学
- 気分障害研究
- 精神疾患の疫学
背景:
- 気分障害における混合性特徴は認識されていますが、一貫した有病率の推定値が不足しています。
- 以前の系統的レビューは、大うつ病性障害(MDD)および双極性障害(BD)の混合性特徴の最新の有病率データが必要であることを強調しています。
研究 の 目的:
- MDDおよびBDにおける混合性特徴の最新の有病率推定値を提供すること。
- 異なる診断基準(DSM-5 vs. ≥3の反対極性特徴)に基づく有病率を比較すること。
主な方法:
- MDDまたはBDの成人を対象とした研究を対象とした5つのデータベースを横断する系統的文献検索を実施しました。
- DSM-5基準を使用して混合性特徴を評価した、または≥3の反対極性特徴を特定した研究を含めました。
- 独立したデータ抽出と、信頼区間を伴うプールされた有病率の計算を実施しました。
主要な成果:
- 5つの世界地域からの26の研究を分析しました。
- 混合性特徴は、MDDエピソードの18.1%およびBDエピソード(うつ病および[軽躁]病エピソード)の32.8%-34.8%で見られました。
- 有病率は、MDDと比較してBDでほぼ2倍であり、診断基準によって大きく異なりました。
結論:
- 混合性特徴は気分障害、特に双極性障害において非常に一般的です。
- 現在の有病率の推定値は、採用された診断基準の影響を強く受けます。
- 予後的および治療的影響を理解するためには、診断定義の調和が不可欠です。
関連する概念動画
Bipolar Disorder
586
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
586
Depressive Disorders: Etiology
408
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
408
Depressive Disorders: MDD and Dysthymia
564
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
564
Depression: Overview
741
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
741
Mania and Antimanic Drugs: Overview
526
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
526
Antidepressant Drugs: MAOIs and Other Agents
765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765

